These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 9613981

  • 61. Evidence for an oncogenic role of AHI-1 in Sezary syndrome, a leukemic variant of human cutaneous T-cell lymphomas.
    Ringrose A, Zhou Y, Pang E, Zhou L, Lin AE, Sheng G, Li XJ, Weng A, Su MW, Pittelkow MR, Jiang X.
    Leukemia; 2006 Sep; 20(9):1593-601. PubMed ID: 16838023
    [Abstract] [Full Text] [Related]

  • 62. Immunohistochemical studies using monoclonal antibodies on lymph nodes from patients with mycosis fungoides and Sézary's syndrome.
    Willemze R, Scheffer E, Meijer CJ.
    Am J Pathol; 1985 Jul; 120(1):46-54. PubMed ID: 3893151
    [Abstract] [Full Text] [Related]

  • 63. Immunophenotypic identification of Sezary cells in peripheral blood.
    Bogen SA, Pelley D, Charif M, McCusker M, Koh H, Foss F, Garifallou M, Arkin C, Zucker-Franklin D.
    Am J Clin Pathol; 1996 Dec; 106(6):739-48. PubMed ID: 8980349
    [Abstract] [Full Text] [Related]

  • 64. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases.
    Klemke CD, Booken N, Weiss C, Nicolay JP, Goerdt S, Felcht M, Géraud C, Kempf W, Assaf C, Ortonne N, Battistella M, Bagot M, Knobler R, Quaglino P, Arheiliger B, Santucci M, Jansen P, Vermeer MH, Willemze R.
    Br J Dermatol; 2015 Jul; 173(1):93-105. PubMed ID: 25864856
    [Abstract] [Full Text] [Related]

  • 65. [Epidermotropic T lymphomas].
    Sigal-Nahum M, Brousse N, Belaïch S.
    Rev Prat; 1987 May 01; 37(25):1423-31. PubMed ID: 3495856
    [No Abstract] [Full Text] [Related]

  • 66. Functional properties in Sézary cells with an unusual phenotype.
    Bernengo MG, Meregalli M, Jemma C, Lisa F.
    Clin Immunol Immunopathol; 1985 Dec 01; 37(3):298-311. PubMed ID: 2932270
    [Abstract] [Full Text] [Related]

  • 67. KIR3DL2/CpG ODN interaction mediates Sézary syndrome malignant T cell apoptosis.
    Ghazi B, Thonnart N, Bagot M, Bensussan A, Marie-Cardine A.
    J Invest Dermatol; 2015 Jan 01; 135(1):229-237. PubMed ID: 25007046
    [Abstract] [Full Text] [Related]

  • 68. Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.
    van der Fits L, Out-Luiting JJ, Tensen CP, Zoutman WH, Vermeer MH.
    J Invest Dermatol; 2014 Oct 01; 134(10):2639-2647. PubMed ID: 24756111
    [Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70. Sézary syndrome with elevated serum IgE and hypereosinophilia: role of dysregulated cytokine production.
    Borish L, Dishuck J, Cox L, Mascali JJ, Williams J, Rosenwasser LJ.
    J Allergy Clin Immunol; 1993 Jul 01; 92(1 Pt 1):123-31. PubMed ID: 8335848
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72. A clonal CD4-positive T-cell line established from the blood of a patient with Sézary syndrome.
    Abrams JT, Lessin S, Ghosh SK, Ju W, Vonderheid EC, Nowell P, Murphy G, Elfenbein B, DeFreitas E.
    J Invest Dermatol; 1991 Jan 01; 96(1):31-7. PubMed ID: 1987293
    [Abstract] [Full Text] [Related]

  • 73. Sézary syndrome: phenotypic and functional characterization of the neoplastic cells.
    Ralfkiaer E, Wantzin GL, Larsen JK, Andersen V, Geisler C, Plesner T, Thomsen K.
    Scand J Haematol; 1985 May 01; 34(5):385-93. PubMed ID: 3874419
    [Abstract] [Full Text] [Related]

  • 74. Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma.
    Bégué E, Jean-Louis F, Bagot M, Jauliac S, Cayuela JM, Laroche L, Parquet N, Bachelez H, Bensussan A, Courtois G, Michel L.
    Blood; 2012 Jul 05; 120(1):143-54. PubMed ID: 22627769
    [Abstract] [Full Text] [Related]

  • 75. Interleukin-16 as a marker of Sézary syndrome onset and stage.
    Richmond J, Tuzova M, Parks A, Adams N, Martin E, Tawa M, Morrison L, Chaney K, Kupper TS, Curiel-Lewandrowski C, Cruikshank W.
    J Clin Immunol; 2011 Feb 05; 31(1):39-50. PubMed ID: 20878214
    [Abstract] [Full Text] [Related]

  • 76. Sézary syndrome with T/NK phenotype: A variant phenotype or a distinct clinical entity?
    Matos DM, Kaufman J, Scrideli CA, Falcão RP.
    Cytometry B Clin Cytom; 2018 Jul 05; 94(4):561-563. PubMed ID: 27145066
    [No Abstract] [Full Text] [Related]

  • 77. A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival.
    Hoffmann JC, Atwater SK, Hong E, Kumar J, Khodadoust M, Kim Y, Ohgami RS.
    Am J Dermatopathol; 2020 Jun 05; 42(6):389-396. PubMed ID: 32433315
    [Abstract] [Full Text] [Related]

  • 78. Imbalanced IL-1B and IL-18 Expression in Sézary Syndrome.
    Manfrere KCG, Torrealba MP, Ferreira FM, de Sousa ESA, Miyashiro D, Teixeira FME, Custódio RWA, Nakaya HI, Ramos YAL, Sotto MN, Woetmann A, Ødum N, Duarte AJDS, Sanches JA, Sato MN.
    Int J Mol Sci; 2023 Feb 28; 24(5):. PubMed ID: 36902104
    [Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. Regulation gone wrong: a subset of Sézary patients have malignant regulatory T cells.
    Clark RA.
    J Invest Dermatol; 2009 Dec 28; 129(12):2747-50. PubMed ID: 19901946
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.